EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational design of multi-epitope vaccine for Chandipura virus using an immunoinformatics approach

Ramtin Naderian, Sajjad Ahmad, Mojgan Rahmanian, Shahrzad Aghaamoo, Aryan Rahbar, Omid Pajand iD, Akram Alizadeh, Shahin Nazarian, Samira Sanami iD, Majid Eslami

PLOS One · 23.10.2025 · 20 (10) · e0335147

DOI: 10.1371/journal.pone.0335147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 23.10.2025. Verfasst von Ramtin Naderian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran. Hauptthemen laut MEDLINE: Viral Vaccines, Epitopes, B-Lymphocyte, Epitopes, T-Lymphocyte, Vesiculovirus. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Semnan University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chandipura virus (CHPV) is endemic in India, with frequent outbreaks reported. No approved medicines or vaccines exist for CHPV. We aimed to develop a multi-epitope vaccine for CHPV using immunoinformatics approaches. In this study, a multi-epitope vaccine construct was developed by combining 11 CTL epitopes, 2 HTL epitopes, and 1 linear B-cell epitope from glycoprotein (G) with 1 EAAAK linker, 10 AAY linkers, 2 GPGPG linkers, 1 KK linker, and adjuvant (RS-09 peptide). We predicted and optimized the vaccine’s protein structure. Furthermore, the vaccine 3D structure was docked with Toll-like receptor 4 (TLR4) using the Cluspro 2.0 server, and the docked complex was analyzed using molecular dynamics (MD) simulation by the assisted model building with energy refinement (AMBER) v.20 package. The vaccine’s immune simulation profile was determined, and the vaccine sequence was reverse translated and in silico cloned into the pET28a (+). The vaccine’s population coverage was 99.79% across the worldwide. The vaccine was soluble, non-allergenic and non-toxic, with high levels of antigenicity. The quality of the vaccine’s 3D structure improved following refining, and the number of residues in the most favoured regions of the Ramachandran plot increased by 94.2%. The molecular docking, with a docking score of −1157 kcal/mol, and MD simulation results revealed a robust interaction and remarkable stability between the vaccine and TLR4. The immune response simulation indicated a decrease in antigen levels and an increase in interferon‐gamma (IFN‐γ) and interleukin-2 (IL-2) concentrations after each injection. In silico results indicate that this vaccine possesses significant promise against CHPV; however, laboratory and animal studies are necessary to validate our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteVesiculovirusRhabdoviridae InfectionsMolecular Docking SimulationMolecular Dynamics SimulationToll-Like Receptor 4Computational BiologyHumansAnimalsImmunoinformatics

Substanzen

Viral VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteToll-Like Receptor 4

Autor:innen und Institutionen

  • Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan.
  • Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Department of Electrical and Computer Engineering, University of Southern California, Los Angeles, California, United States of America.
  • Department of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran.

ORCID-Profile: Omid Pajand, Samira Sanami

Förderung

  • Semnan University of Medical Sciences and Health Services

Zitieren

APA

Naderian, R., Ahmad, S., Rahmanian, M., Aghaamoo, S., Rahbar, A., Pajand, O., Alizadeh, A., Nazarian, S., Sanami, S., & Eslami, M. (2025). Rational design of multi-epitope vaccine for Chandipura virus using an immunoinformatics approach. PLOS One, 20(10), e0335147. https://doi.org/10.1371/journal.pone.0335147

Vancouver

Naderian R, Ahmad S, Rahmanian M, Aghaamoo S, Rahbar A, Pajand O, et al. Rational design of multi-epitope vaccine for Chandipura virus using an immunoinformatics approach. PLOS One. 2025;20(10):e0335147. doi:10.1371/journal.pone.0335147

BibTeX
@article{Naderian2025,
  author = {Naderian, Ramtin and Ahmad, Sajjad and Rahmanian, Mojgan and Aghaamoo, Shahrzad and Rahbar, Aryan and Pajand, Omid and Alizadeh, Akram and Nazarian, Shahin and Sanami, Samira and Eslami, Majid},
  title = {Rational design of multi-epitope vaccine for Chandipura virus using an immunoinformatics approach},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {10},
  pages = {e0335147},
  doi = {10.1371/journal.pone.0335147}
}
Kostenlos starten →